Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 27

2.

High Constitutive Cytokine Release by Primary Human Acute Myeloid Leukemia Cells Is Associated with a Specific Intercellular Communication Phenotype.

Reikvam H, Aasebø E, Brenner AK, Bartaula-Brevik S, Grønningsæter IS, Forthun RB, Hovland R, Bruserud Ø.

J Clin Med. 2019 Jul 4;8(7). pii: E970. doi: 10.3390/jcm8070970.

3.

A Kinase Inhibitor with Anti-Pim Kinase Activity is a Potent and Selective Cytotoxic Agent Toward Acute Myeloid Leukemia.

Bjørnstad R, Aesoy R, Bruserud Ø, Brenner AK, Giraud F, Dowling TH, Gausdal G, Moreau P, Døskeland SO, Anizon F, Herfindal L.

Mol Cancer Ther. 2019 Mar;18(3):567-578. doi: 10.1158/1535-7163.MCT-17-1234. Epub 2019 Jan 24.

PMID:
30679386
4.

The Capacity of Long-Term in Vitro Proliferation of Acute Myeloid Leukemia Cells Supported Only by Exogenous Cytokines Is Associated with a Patient Subset with Adverse Outcome.

Brenner AK, Aasebø E, Hernandez-Valladares M, Selheim F, Berven F, Grønningsæter IS, Bartaula-Brevik S, Bruserud Ø.

Cancers (Basel). 2019 Jan 10;11(1). pii: E73. doi: 10.3390/cancers11010073.

5.

Proteomic Profiling of Primary Human Acute Myeloid Leukemia Cells Does Not Reflect Their Constitutive Release of Soluble Mediators.

Aasebø E, Hernandez-Valladares M, Selheim F, Berven FS, Brenner AK, Bruserud Ø.

Proteomes. 2018 Dec 20;7(1). pii: E1. doi: 10.3390/proteomes7010001.

6.

S100 Proteins in Acute Myeloid Leukemia.

Brenner AK, Bruserud Ø.

Neoplasia. 2018 Dec;20(12):1175-1186. doi: 10.1016/j.neo.2018.09.007. Epub 2018 Oct 23. Review.

7.

Immunological Heterogeneity of Healthy Peripheral Blood Stem Cell Donors-Effects of Granulocyte Colony-Stimulating Factor on Inflammatory Responses.

Tvedt THA, Melve GK, Tsykunova G, Ahmed AB, Brenner AK, Bruserud Ø.

Int J Mol Sci. 2018 Sep 22;19(10). pii: E2886. doi: 10.3390/ijms19102886.

8.

Two acute myeloid leukemia patient subsets are identified based on the constitutive PI3K-Akt-mTOR signaling of their leukemic cells; a functional, proteomic, and transcriptomic comparison.

Nepstad I, Hatfield KJ, Aasebø E, Hernandez-Valladares M, Brenner AK, Bartaula-Brevik S, Berven F, Selheim F, Skavland J, Gjertsen BT, Reikvam H, Bruserud Ø.

Expert Opin Ther Targets. 2018 Jul;22(7):639-653. doi: 10.1080/14728222.2018.1487401. Epub 2018 Jun 22.

PMID:
29889583
9.

Resistance to the Antiproliferative In Vitro Effect of PI3K-Akt-mTOR Inhibition in Primary Human Acute Myeloid Leukemia Cells Is Associated with Altered Cell Metabolism.

Nepstad I, Reikvam H, Brenner AK, Bruserud Ø, Hatfield KJ.

Int J Mol Sci. 2018 Jan 27;19(2). pii: E382. doi: 10.3390/ijms19020382.

10.

The Possible Importance of β3 Integrins for Leukemogenesis and Chemoresistance in Acute Myeloid Leukemia.

Johansen S, Brenner AK, Bartaula-Brevik S, Reikvam H, Bruserud Ø.

Int J Mol Sci. 2018 Jan 15;19(1). pii: E251. doi: 10.3390/ijms19010251. Review.

11.

The constitutive protease release by primary human acute myeloid leukemia cells.

Honnemyr M, Bruserud Ø, Brenner AK.

J Cancer Res Clin Oncol. 2017 Oct;143(10):1985-1998. doi: 10.1007/s00432-017-2458-7. Epub 2017 Jun 19.

PMID:
28631213
12.

CDC25 Inhibition in Acute Myeloid Leukemia-A Study of Patient Heterogeneity and the Effects of Different Inhibitors.

Brenner AK, Reikvam H, Rye KP, Hagen KM, Lavecchia A, Bruserud Ø.

Molecules. 2017 Mar 11;22(3). pii: E446. doi: 10.3390/molecules22030446.

13.

Patients with acute myeloid leukemia can be subclassified based on the constitutive cytokine release of the leukemic cells; the possible clinical relevance and the importance of cellular iron metabolism.

Brenner AK, Tvedt TH, Nepstad I, Rye KP, Hagen KM, Reikvam H, Bruserud Ø.

Expert Opin Ther Targets. 2017 Apr;21(4):357-369. doi: 10.1080/14728222.2017.1300255. Epub 2017 Mar 3.

PMID:
28281897
14.

Mesenchymal Stem Cells Support Survival and Proliferation of Primary Human Acute Myeloid Leukemia Cells through Heterogeneous Molecular Mechanisms.

Brenner AK, Nepstad I, Bruserud Ø.

Front Immunol. 2017 Feb 9;8:106. doi: 10.3389/fimmu.2017.00106. eCollection 2017.

16.

Rethinking the role of osteopontin in human acute myeloid leukemia.

Brenner AK, Aasebø E, Hernandez-Valladares M, Selheim F, Berven F, Bruserud Ø.

Leuk Lymphoma. 2017 Jun;58(6):1494-1497. doi: 10.1080/10428194.2016.1243682. Epub 2016 Oct 14. No abstract available.

PMID:
27739925
17.
18.

The cytokine-mediated crosstalk between primary human acute myeloid cells and mesenchymal stem cells alters the local cytokine network and the global gene expression profile of the mesenchymal cells.

Reikvam H, Brenner AK, Hagen KM, Liseth K, Skrede S, Hatfield KJ, Bruserud Ø.

Stem Cell Res. 2015 Nov;15(3):530-541. doi: 10.1016/j.scr.2015.09.008. Epub 2015 Sep 25.

19.

Effects of cytarabine on activation of human T cells - cytarabine has concentration-dependent effects that are modulated both by valproic acid and all-trans retinoic acid.

Ersvaer E, Brenner AK, Vetås K, Reikvam H, Bruserud Ø.

BMC Pharmacol Toxicol. 2015 May 2;16:12. doi: 10.1186/s40360-015-0012-2.

20.

Emerging therapeutic targets for the treatment of human acute myeloid leukemia (part 1) - gene transcription, cell cycle regulation, metabolism and intercellular communication.

Reikvam H, Hauge M, Brenner AK, Hatfield KJ, Bruserud Ø.

Expert Rev Hematol. 2015 Jun;8(3):299-313. doi: 10.1586/17474086.2015.1032935. Epub 2015 Apr 3. Review.

PMID:
25835070

Supplemental Content

Loading ...
Support Center